Acrivon Therapeutics (ACRV) Net Cash Flow (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Net Cash Flow of -$7.4 million for Q1 2026, down 1021.08% year-over-year from $808177.9 in Q1 2025, and down 222.13% quarter-over-quarter from $6.1 million in Q4 2025.
Acrivon Therapeutics (ACRV) Net Cash Flow (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Net Cash Flow for 6 consecutive years, with -$7.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 1021.08% year-over-year to -$7.4 million; the TTM figure through Mar 2026 stood at -$5.1 million (down 135.55% YoY), while the FY2025 annual figure was $1.7 million, down 53.0% from the prior year.
- Net Cash Flow declined to -$7.4 million in Q1 2026 per ACRV's latest filing, from $6.1 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $21.4 million in Q2 2024 and bottomed at -$51.8 million in Q3 2022.
- Historically, Net Cash Flow has averaged -$3.9 million across 5 years, with a median of -$2.8 million in 2024.
- Annual changes were most pronounced in 2023 — Net Cash Flow soared 340.49% — and 2026, when it plunged 1021.08%.
- Acrivon Therapeutics' Net Cash Flow stood at -$2.6 million in 2022, then jumped by 340.49% to $6.2 million in 2023, then sank by 158.37% to -$3.6 million in 2024, then jumped by 269.54% to $6.1 million in 2025, then slumped by 222.13% to -$7.4 million in 2026.
- Business Quant data shows ACRV's Net Cash Flow at -$7.4 million in Q1 2026, $6.1 million in Q4 2025, and -$6.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - | 7.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.35 Mn |
| Jun 30, 2026 | 7.35 Mn |
| Mar 31, 2026 | -7.44 Mn |
| Mar 31, 2026 | -7.44 Mn |
| Dec 31, 2025 | 6.10 Mn |
| Dec 31, 2025 | 6.10 Mn |
| Sep 30, 2025 | -6.49 Mn |
| Sep 30, 2025 | -6.49 Mn |
| Jun 30, 2025 | 2.74 Mn |
| Jun 30, 2025 | 2.74 Mn |
| Mar 31, 2025 | -664,000.00 |
| Mar 31, 2025 | -664,000.00 |
| Dec 31, 2024 | -3.60 Mn |
| Dec 31, 2024 | -3.60 Mn |
| Sep 30, 2024 | -2.82 Mn |
| Sep 30, 2024 | -2.82 Mn |
| Jun 30, 2024 | 21.40 Mn |
| Jun 30, 2024 | 21.40 Mn |
| Mar 31, 2024 | -11.41 Mn |
| Mar 31, 2024 | -11.41 Mn |